TAKEDA PHARMACEUTICAL CO LTD - 08 Dec 2025 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship: 10%+ Owner
Issuer ticker: OVID
Reported as of: 08 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Dec 2025, 21:19:26 UTC
Prior SEC filing: 19 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Max Heuer, Authorized Signatory, Takeda Pharmaceutical Company Limited

Key filing fact

TAKEDA PHARMACEUTICAL CO LTD filed Form 4 for Ovid Therapeutics Inc. (OVID) on 09 Dec 2025.

Key facts

This page summarizes TAKEDA PHARMACEUTICAL CO LTD's Form 4 filing for Ovid Therapeutics Inc. (OVID).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Dec 2025, 21:19.

Change

Previous filing in this sequence was filed on 19 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001395064 Primary reporting owner

TAKEDA PHARMACEUTICAL CO LTD

Relationship: 10%+ Owner
Address: 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, JAPAN
Signature: /s/ Max Heuer, Authorized Signatory, Takeda Pharmaceutical Company Limited
Signature date: 09 Dec 2025

CIK 0001716229

Takeda Pharmaceuticals U.S.A., Inc.

Relationship: 10%+ Owner
Address: 95 HAYDEN AVENUE, LEXINGTON
Signature: /s/ Paul Sundberg, Assistant Secretary of Takeda Pharmaceuticals U.S.A., Inc.
Signature date: 09 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OVID transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +1,250,000
Change %: +22%
Price: $0.000000
Shares after: 7,000,000
Date: 08 Dec 2025
Ownership: See Explanation of Responses
Footnotes: F1, F2

OVID holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,781,996
Date: 08 Dec 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVID transaction Derivative

Series A Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -1,250
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Dec 2025
Ownership: See Explanation of Responses
Underlying class: Common Stock
Underlying amount: 1,250
Exercise price: $0.000000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.

Footnote F2

The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.

Footnote F3

The Preferred Stock had no expiration date.